Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ)
CNY 2.36
(-1.26%)
CNY 2.36
(-1.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.35 Billion CNY | -41.92% |
| 2022 | 2.25 Billion CNY | 5.26% |
| 2021 | 2.13 Billion CNY | -6.11% |
| 2020 | 2.27 Billion CNY | -30.15% |
| 2019 | 3.26 Billion CNY | -5.47% |
| 2018 | 3.45 Billion CNY | 117.0% |
| 2017 | 1.59 Billion CNY | 94.07% |
| 2016 | 819.56 Million CNY | -1.72% |
| 2015 | 833.9 Million CNY | 20.48% |
| 2014 | 692.16 Million CNY | -16.42% |
| 2013 | 828.11 Million CNY | 181.77% |
| 2012 | 293.89 Million CNY | 90.68% |
| 2011 | 154.13 Million CNY | 24.84% |
| 2010 | 123.46 Million CNY | 45.38% |
| 2009 | 84.92 Million CNY | 33.6% |
| 2008 | 63.56 Million CNY | 81.13% |
| 2007 | 35.09 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 270.47 Million CNY | 907.16% |
| 2024 Q3 | 267.6 Million CNY | 2.73% |
| 2024 Q2 | 253.27 Million CNY | -6.36% |
| 2023 Q1 | 465.5 Million CNY | -17.27% |
| 2023 Q3 | 402.16 Million CNY | -25.07% |
| 2023 Q4 | 26.85 Million CNY | -93.32% |
| 2023 FY | 1.3 Billion CNY | -41.92% |
| 2023 Q2 | 536.74 Million CNY | 15.3% |
| 2022 Q2 | 551.87 Million CNY | 5.53% |
| 2022 Q1 | 522.96 Million CNY | -12.34% |
| 2022 Q4 | 562.66 Million CNY | -8.5% |
| 2022 Q3 | 614.96 Million CNY | 11.43% |
| 2022 FY | 2.25 Billion CNY | 5.26% |
| 2021 Q2 | 536 Million CNY | 12.02% |
| 2021 FY | 2.13 Billion CNY | -6.11% |
| 2021 Q3 | 528.93 Million CNY | -1.32% |
| 2021 Q1 | 478.49 Million CNY | -36.99% |
| 2021 Q4 | 596.56 Million CNY | 12.79% |
| 2020 Q1 | 381.54 Million CNY | -55.04% |
| 2020 FY | 2.27 Billion CNY | -30.15% |
| 2020 Q3 | 578.44 Million CNY | 3.69% |
| 2020 Q4 | 759.42 Million CNY | 31.29% |
| 2020 Q2 | 557.85 Million CNY | 46.21% |
| 2019 FY | 3.26 Billion CNY | -5.47% |
| 2019 Q1 | 781.88 Million CNY | -23.64% |
| 2019 Q2 | 889.1 Million CNY | 13.71% |
| 2019 Q3 | 743.2 Million CNY | -16.41% |
| 2019 Q4 | 848.65 Million CNY | 14.19% |
| 2018 Q2 | 775.18 Million CNY | 6.6% |
| 2018 Q3 | 925.21 Million CNY | 19.35% |
| 2018 Q1 | 727.21 Million CNY | -3.83% |
| 2018 Q4 | 1.02 Billion CNY | 10.67% |
| 2018 FY | 3.45 Billion CNY | 117.0% |
| 2017 Q1 | 171.43 Million CNY | -38.39% |
| 2017 FY | 1.59 Billion CNY | 94.07% |
| 2017 Q3 | 412.65 Million CNY | 64.87% |
| 2017 Q4 | 756.17 Million CNY | 83.25% |
| 2017 Q2 | 250.28 Million CNY | 46.0% |
| 2016 Q4 | 278.24 Million CNY | 43.61% |
| 2016 Q2 | 171.41 Million CNY | -2.69% |
| 2016 Q1 | 176.15 Million CNY | -31.45% |
| 2016 FY | 819.56 Million CNY | -1.72% |
| 2016 Q3 | 193.75 Million CNY | 13.04% |
| 2015 FY | 833.9 Million CNY | 20.48% |
| 2015 Q3 | 201.93 Million CNY | 0.07% |
| 2015 Q2 | 201.79 Million CNY | 16.51% |
| 2015 Q1 | 173.2 Million CNY | -5.85% |
| 2015 Q4 | 256.97 Million CNY | 27.25% |
| 2014 Q1 | 118.78 Million CNY | -41.19% |
| 2014 FY | 692.16 Million CNY | -16.42% |
| 2014 Q3 | 191.69 Million CNY | -3.05% |
| 2014 Q2 | 197.72 Million CNY | 66.45% |
| 2014 Q4 | 183.95 Million CNY | -4.04% |
| 2013 Q2 | 287.25 Million CNY | 143.44% |
| 2013 Q3 | 220.85 Million CNY | -23.12% |
| 2013 Q4 | 202 Million CNY | -8.54% |
| 2013 FY | 828.11 Million CNY | 181.77% |
| 2013 Q1 | 118 Million CNY | 8.15% |
| 2012 Q2 | 69.61 Million CNY | 27.9% |
| 2012 Q4 | 109.1 Million CNY | 79.63% |
| 2012 FY | 293.89 Million CNY | 90.68% |
| 2012 Q1 | 54.43 Million CNY | -9.91% |
| 2012 Q3 | 60.74 Million CNY | -12.75% |
| 2011 Q1 | 26.5 Million CNY | -39.1% |
| 2011 Q2 | 30.29 Million CNY | 14.28% |
| 2011 Q3 | 36.91 Million CNY | 21.87% |
| 2011 Q4 | 60.41 Million CNY | 63.65% |
| 2011 FY | 154.13 Million CNY | 24.84% |
| 2010 Q4 | 43.52 Million CNY | 61.31% |
| 2010 Q2 | 30.39 Million CNY | 34.66% |
| 2010 Q3 | 26.98 Million CNY | -11.22% |
| 2010 FY | 123.46 Million CNY | 45.38% |
| 2010 Q1 | 22.56 Million CNY | -5.34% |
| 2009 Q4 | 23.84 Million CNY | -6.88% |
| 2009 FY | 84.92 Million CNY | 33.6% |
| 2009 Q2 | 16.28 Million CNY | -11.52% |
| 2009 Q1 | 18.4 Million CNY | 0.0% |
| 2009 Q3 | 25.6 Million CNY | 57.21% |
| 2008 FY | 63.56 Million CNY | 81.13% |
| 2007 FY | 35.09 Million CNY | 0.0% |